Previous studies have confirmed that FMO3 knockout can significantly reduce gut-microbiota-dependent TMAO-induced atherosclerosis and thrombosis, suggesting that therapies targeting FMO3 may reduce the ischemic stroke risk [60,177,178]. The gene discussed is FMO3; the disease is ischemic stroke.